CARsgen Therapeutics Holdings Limited (HKG:2171)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
19.20
+0.14 (0.73%)
Jun 6, 2025, 4:08 PM HKT

CARsgen Therapeutics Holdings Company Description

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States.

Its products include CT053 for the treatment of relapsed/refractory multiple myeloma. The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial for patients with targeting Glypican-3 positive to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL).

In addition, it is developing CT0590 and CT059X, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma and R/R PCL, as well as KJ-C2114 that are in the pre-clinical stage for the treatment of solid tumors; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I.

Further, the company develops KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence.

It has collaborated with Moderna, Inc. to investigate satricabtagene autoleucel in combination with Moderna’s investigational Claudin18.2 mRNA product.; and East China University of Science and Technology (ECUST) to leverage synergies between academic and industrial resources.

The company was founded in 2014 and is headquartered in Shanghai, China.

CARsgen Therapeutics Holdings Limited
Country Cayman Islands
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 465
CEO Zonghai Li

Contact Details

Address:
No. 466 Yindu Road
Shanghai
China
Phone 86 21 6450 1828
Website carsgen.com

Stock Details

Ticker Symbol 2171
Exchange Hong Kong Stock Exchange
Fiscal Year January - December
Reporting Currency CNY
ISIN Number KYG1996C1006
SIC Code 2836

Key Executives

Name Position
Dr. Zonghai Li M.D., Ph.D. Co-Founder, Chief Executive Officer, Chief Scientific Officer and Chairman of the Board
Dr. Huamao Wang Ph.D. Co-Founder, Chief Operating Officer and Executive Director
Dr. Hua Jiang Executive Director
Wing Yat Lui Company Secretary